ImmPACT Bio

Company Overview

Snapshot

Founded in November 2016, ImmPACT Bio operates with 11–50 employees and has raised a total of $137 million across 4 funding rounds from 9 investors. The company was acquired by Lyell Immunopharma in October 2024.

Business overview

ImmPACT Bio is a clinical-stage company focused on developing transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's core technology utilizes logic-gate-based CAR T platforms designed to overcome key challenges in cancer treatment, including preventing antigen escape, mitigating "on-target off-tumor" toxicities, and addressing the immunosuppressive tumor microenvironment. ImmPACT Bio operates within the Health Tech & Life Sciences sector, specifically targeting the biopharmaceutical, oncology, and cell therapy markets.

Strategic signal

In October 2024, Lyell Immunopharma completed its acquisition of ImmPACT Bio. This strategic move indicates a consolidation within the CAR T-cell therapy space, with Lyell Immunopharma prioritizing ImmPACT Bio's next-generation therapies to enhance its pipeline. For investors, this acquisition signals validation of ImmPACT Bio's technology and a potential acceleration of its therapeutic development under a larger entity.

Company Intelligence Q&A

What was the most significant recent corporate development for ImmPACT Bio?

In October 2024, ImmPACT Bio was acquired by Lyell Immunopharma. This acquisition was completed to integrate ImmPACT Bio's next-generation CAR T-cell therapies into Lyell Immunopharma's pipeline.

Did ImmPACT Bio receive any grants recently?

In February 2024, ImmPACT Bio was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for the Phase 1b/2 development of IMPT-514, a CD19/CD20 bispecific CAR T-cell therapy for refractory lupus nephritis and systemic lupus erythematosus.

When did ImmPACT Bio announce FDA clearance for a novel bispecific CAR?

In January 2023, ImmPACT Bio announced that the FDA cleared its Investigational New Drug (IND) application for a novel bispecific CAR designed to treat aggressive B-cell lymphoma.

When did ImmPACT Bio complete its Series B financing round?

In January 2022, ImmPACT Bio closed its Series B financing round. This round included investment from venBio and OrbiMed.

What was a notable leadership appointment at ImmPACT Bio?

In September 2022, ImmPACT Bio appointed Jonathan Benjamin, M.D., Ph.D., as its Chief Medical Officer, strengthening its leadership team for clinical development.